share_log

Cantor Fitzgerald Initiates Coverage On Sorrento Therapeutics With Overweight Rating, Announces Price Target of $5

Cantor Fitzgerald Initiates Coverage On Sorrento Therapeutics With Overweight Rating, Announces Price Target of $5

坎特·菲茨杰拉德以超重評級啟動索倫托治療的覆蓋範圍,宣布目標價格為 5 美元
Benzinga Real-time News ·  2022/11/02 09:28

Cantor Fitzgerald analyst Brandon Folkes initiates coverage on Sorrento Therapeutics (NASDAQ:SRNE) with a Overweight rating and announces Price Target of $5.

Cantor Fitzgerald分析師布蘭登·福克斯對索倫託治療公司(納斯達克:SRNE)發起增持評級,並宣佈目標價為5美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論